-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $34

Benzinga·07/10/2026 10:10:19
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $32 to $34.